Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1999 Dec;90(12):1380–1386. doi: 10.1111/j.1349-7006.1999.tb00723.x

Interaction of Docetaxel (“Taxotere”) with Human P‐Glycoprotein

Katsuro Shirakawa 1, Kohji Takara 2, Yusuke Tanigawara 3, Nobuo Aoyama 1, Masato Kasuga 1, Fusao Komada 2,†, Toshiyuki Sakaeda 2, Katsuhiko Okumura 2,✉
PMCID: PMC5926029  PMID: 10665657

Abstract

The interaction of docetaxel (“Taxotere”) with P‐glycoprotein (P‐gp) was examined using porcine kidney epithelial LLC‐PK1 and LLC‐GA5‐COL150 cells, overexpressing human P‐gp selectively on the apical plasma membrane by transfection of human MDR1cDNA into the LLC‐PK1 cells. The basal‐to‐apical transport of [14C]docetaxel in LLC‐GA5‐COL150 cells significantly exceeded that in LLC‐PK1 cells, but the apical‐to‐basal transport was decreased in LLC‐GA5‐COL150 cells. The intracellular accumulation after its basal or apical application to LLC‐GA5‐COL150 cells was 4‐ to 20‐fold lower than that of LLC‐PK1 cells. Multidrug resistance (MDR) modulators, i.e., cyclosporin A and SDZ PSC 833, inhibited the basal‐to‐apical transport and increased the apical‐to‐basal transport of [14C] docetaxel in LLC‐GA5‐COL150 cells, but verapamil affected only apical‐to‐basal transport. The intracellular accumulation after basal or apical application to LLC‐GA5‐COL150 cells was also increased by these three MDR modulators. These observations demonstrated that docetaxel is a substrate for human P‐gp, suggesting that docetaxel‐drug interactions occur via P‐gp. The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC‐PK1 cells, which endogenously express P‐gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC‐GA5‐COL150 cells. These observations indicate that it is necessary to consider the Pharmacokinetic and pharmacodynamic interactions of docetaxel via P‐gp.

Keywords: Docetaxel, “Taxotere”, P‐Glycoprotein, Multidrug resistance, Transport

Full Text

The Full Text of this article is available as a PDF (164.5 KB).

REFERENCES

  • 1. ) Ringel , I. and Horwitz , S. B.Studies with RP 56976 (taxo‐tere): a semisynthetic analogue of taxol . J. Natl. Cancer Inst. , 83 , 288 – 291 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Clarke , S. J. and Rivory , L. P.Clinical pharmacokinetics of docetaxel . Clin. Pharmacokinet. , 36 , 99 – 114 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Dumontet , C. and Sikic , B. I.Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death . J. Clin. Oncol. , 17 , 1061 – 1070 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Bissery , M. C. , Guenard , D. , Gueritte , V. F. and Lavelle , F.Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue . Cancer Res. , 51 , 4845 – 4852 ( 1991. ). [PubMed] [Google Scholar]
  • 5. ) Riou , J. F. , Naudin , A. and Lavelle , F.Effects of Taxotere on murine and human tumor cell lines . Biochem. Biophys. Res. Commun. , 187 , 164 – 170 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Garcia , P. , Braguer , D. , Carles , G. , Khyari , S. , Barra , Y. , de Ines , C. , Barasoain , I. and Briand , C.Comparative effects of taxol and Taxotere on two different human carcinoma cell lines . Cancer Chemother. Pharmacol. , 34 , 335 – 343 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Hill , B. T. , Whelan , R. D. , Shellard , S. A. , McClean , S. and Hosking , L. K.Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro . Invest. New Drugs , 12 , 169 – 182 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Cortes , J. E. and Docetaxel Pazdur R.J. Clin. Oncol. , 13 , 2643 – 26551995. . [DOI] [PubMed] [Google Scholar]
  • 9. ) Schuller , J. , Czejka , M. , Kletzl , H. , Wirth , M. , Springer , B. , Kriwanek , S. , Terkola , R. and Schernthaner , G.Doxorubi‐cin (DOX) and Taxotere (TXT): a pharmacokinetic (PK) study of the combination in advanced breast cancer (abstr.) . Proc. Am. Soc. Clin. Oncol. , 17 , 205 ( 1998. ). [Google Scholar]
  • 10. ) Shirazi , F. , Bahrami , G. , Fanaee , G. , Lotfolahi , A. , Rouini , M. R. , Stewart , D. J. , Tomiak , E. , Delorme , F. , Vernillet , L. , Bruno , R. and Goel , R.Pharmacokinetic interactions of docetaxel and etoposide (abstr.) . Proc. Am. Soc. Clin. Oncol. , 17 , 252 ( 1998. ). [Google Scholar]
  • 11. ) Tanigawara , Y. , Okamura , N. , Hirai , M. , Yasuhara , M. , Ueda , K. , Kioka , N. , Komano , T. and Hori , R.Transport of digoxin by human P‐glycoprotein expressed in a porcine kidney epithelial cell line (LLC‐PK1) . J. Pharmacol. Exp. Ther. , 263 , 840 – 845 ( 1992. ). [PubMed] [Google Scholar]
  • 12. ) Ueda , K. , Okamura , N. , Hirai , M. , Tanigawara , Y. , Saeki , T. , Kioka , N. , Komano , T. and Hori , R.Human P‐glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone . J. Biol. Chem. , 267 , 24248 – 24252 ( 1992. ). [PubMed] [Google Scholar]
  • 13. ) Tanaka , K. , Hirai , M. , Tanigawara , Y. , Ueda , K. , Takano , M. , Hori , R. and Inui , K.Relationship between expression level of P‐glycoprotein and daunorubicin transport in LLC‐PK1 cells transfected with human MDR1 gene . Biochem. Pharmacol. , 53 , 741 – 746 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Kusunoki , N. , Takara , K. , Tanigawara , Y. , Yamauchi , A. , Ueda , K. , Komada , F. , Ku , Y. , Kuroda , Y. , Saitoh , Y. and Okumura , K.Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P‐glycoprotein . Jpn. J. Cancer Res. , 89 , 1220 – 1228 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. ) Takara , K. , Tanigawara , Y. , Komada , F. , Nishiguchi , K. , Sakaeda , T. and Okumura , K.Cellular pharmacokinetic aspects of reversal effect of itraconazole on P‐glycoprotein‐mediated resistance of anticancer drugs . Biol. Pharm. Bull. , 22 ( 1999. ), in press . [DOI] [PubMed] [Google Scholar]
  • 16. ) Horio , M. , Pastan , I. , Gottesman , M. M. and Handler , J. S.Transepithelial transport of vinblastine by kidney‐derived cell lines. Application of a new kinetic model to estimate in situ Km of the pump . Biochim. Biophys. Acta , 1027 , 116 – 122 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Evers , R. , Zaman , G. J. R. , Deemter , L. , Jansen , H. , Calafat , J. , Oomen , L. C. J. M. , Oude Elferink , R. P. J. , Borst , P. and Schinkel , A. H.Basolateral localization and export activity of the human multidrug resistance‐associated protein in polarized pig kidney cells . J. Clin. Invest. , 97 , 1211 – 1218 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. ) Royer , I. , Monsarrat , B. , Sonnier , M. , Wright , M. and Cresteil , T.Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antine–oplastic drugs . Cancer Res. , 56 , 58 – 65 ( 1996. ). [PubMed] [Google Scholar]
  • 19. ) Marre , F. , Sanderink , G. J. , Sousa , G. , Gaillard , C. , Martinet , M. and Rahmani , R.Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans . Cancer Res. , 56 , 1296 – 1302 ( 1996. ). [PubMed] [Google Scholar]
  • 20. ) Monsarrat , B. , Royer , I. , Wright , M. and Cresteil , T.Biotransformation of taxoids by human cytochromes P450: structure‐activity relationship . Bull. Cancer , 84 , 125 – 133 ( 1997. ). [PubMed] [Google Scholar]
  • 21. ) Urien , S. , Barre , J. , Morin , C. , Paccaly , A. , Montay , G. and Tillement , J. P.Docetaxel serum protein binding with high affinity to alpha1‐acid glycoprotein . Invest. New Drugs , 14 , 147 – 151 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Thiebaut , F. , Tsuruo , T. , Hamada , H. , Gottesman , M. M. , Pastan , I. and Willingham , M. C.Cellular localization of the multidrug‐resistance gene product P‐glycoprotein in normal human tissues . Proc. Natl. Acad. Sci. USA , 84 , 7735 – 7738 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. ) Bosch , I. and Croop , J.P‐Glycoprotein multidrug resistance and cancer . Biochim. Biophys. Acta , 1288 , F37 – F54 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Endicott , J. A. and Ling , V.The biochemistry of P‐glyco‐protein‐mediated multidrug resistance . Annu. Rev. Bio-chem. , 58 , 137 – 171 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Gottesman , M. M. and Pastan , I.Biochemistry of multidrug resistance mediated by the multidrug transporter . Annu. Rev. Biochem. , 62 , 385 – 427 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Baggetto , L. G.Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug‐resistance phenotype. Reversion by new therapies . J. Bioenerg. Biomembr. , 29 , 401 – 413 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Stein , W. D.Kinetics of the multidrug transporter (P–glycoprotein) and its reversal . Physiol. Rev. , 77 , 545 – 590 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Aszalos , A. and Ross , D. D.Biochemical and clinical aspects of efflux pump related resistance to anti‐cancer drugs . Anti cancer Res. , 18 , 2937 – 2944 ( 1998. ). [PubMed] [Google Scholar]
  • 29. ) Samuels , B. L. , Mick , R. , Vogelzang , N. J. , Williams , S. F. , Schilsky , R. L. , Safa , A. R. , O'Brien , S. M. and Ratain , M. J.Modulation of vinblastine resistance with cyclosporin: a phase I study . Clin. Pharmacol. Ther. , 54 , 421 – 429 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Erlichman , C. , Moore , M. , Thiessen , J. J. , Kerr , I. G. , Walker , S. , Goodman , P. , Bjarnason , G. , DeAngelis , C. and Bunting , P.Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin . Cancer Res. , 53 , 4837 – 4842 ( 1993. ). [PubMed] [Google Scholar]
  • 31. ) Rushing , D. A. , Raber , S. R. , Rodvold , K. A. , Piscitelli , S. C. , Plank , G. S. and Tewksbury , D. A.The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer . Cancer , 74 , 834 – 841 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Bartlett , N. L. , Lum , B. L. , Fischer , G. A. , Brophy , N. A. , Ehsan , M. N. , Halsey , J. and Sikic , B. I.Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance . J. Clin. Oncol. , 12 , 835 – 842 ( 1994. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES